Research progress in compound drugs for anti-neurodegenerative diseases

doi:10.19803/j.1672-8629.20240277

Abstract

Abstract: Objective To review the principles of development of compound drugs for neurodegenerative diseases, summarize the related compound drugs developed in recent years and introduce their mechanism of action. Methods By searching relevant literature and databases at home and abroad, compound drugs and that have been developed or entered clinical trials and their mechanisms of action are summarized and analyzed. Results Significant progress has been made in the research on receptor suppressants, monoclonal antibody drugs, neuroprotective drugs and inflammatory suppressants. These drugs can improve memory and cognitive abilities through multi-target effects, significantly delay the progression of the disease, and bring new hopes for improving the quality of life of patients with neurodegenerative diseases and enhancing their motor function. Conclusion Compound drugs for treating neurodegenerative diseases have significant therapeutic advantages, but due to the complicated pathogenesis and irreversible course of disease, the development of these drugs remains challenging. The combination of emerging technologies such as bioinformatics technology, precision medicine, and nanodelivery systems can provide strong technical support and impetus of innovation for the development of compound drugs.

Key words: neurodegenerative diseases, compound drugs, inflammation inhibition, neuroprotection, multi-target, nanodelivery system

CLC Number:

R916
R971

XU Zeao, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, XU Cheng, JIN Hongtao. Research progress in compound drugs for anti-neurodegenerative diseases[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 967-972.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240277

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/967

References

[1] REN R, QI J, LIN S, et al.The China Alzheimer report 2022[J]. Gen Psychiatr, 2022, 35(1): e100751.
[2] TYSNES OB, STORSTEIN A.Epidemiology of Parkinson’s disease[J]. J Neural Transm (Vienna), 2017, 124(8): 901-905.
[3] CHEN L, ZHANG B, CHEN R, et al.Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China[J]. J Neurol Neurosurg Psychiatry, 2015, 86(10): 1075-1081.
[4] TELEANU DM, NICULESCU AG, LUNGU II, et al.An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(11): 5938.
[5] LU JM, LI ZY, GITLER DA, et al.Small molecule targeting strategies for“undruggable”targets in neurodegenerative diseases[J]. Science Bulletin, 2023, 68(16): 1715-1718.
[6] KHALAF K, TORNESE P, COCCO A, et al.Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases[J]. Translational Neurodegeneration, 2022, 11(1): 33.
[7] GENG WQ, YU Y, ZHONG YQ.Research progress on nanodrug delivery systems for the treatment of neurodegenerative diseases[J]. Herald of Medicine(医学导报), 2016, 35(1): 66-70.
[8] CAO Y, JIANG C.Progress in the research of brain-targeted nanomedicine delivery systems[J]. Basic ＆ Clinical Medicine(基础医学与临床), 2022, 42(1): 2-14.
[9] XU F, WU Y, YANG Q, et al.Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment[J]. Adv Mater, 2022, 34(49): e2207107.
[10] YANG D, ZHANG W, ZHANG H, et al.Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics[J]. Theranostics, 2020, 10(8): 3684-3707.
[11] FAN C, LI Y, LAN T, et al.Microglia secrete miR-146a-5p-containing exosomes to regulate neurogenesis in depression[J]. Mol Ther, 2022, 30(3): 1300-1314.
[12] TABRIZI SJ, ESTEVEZ-FRAGA C, VAN ROON-MOM WMC, et al. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities[J]. Lancet Neurol, 2022, 21(7): 645-658.
[13] KUMAR A, GUPTA V, SHARMA S, Donepezil[M]. Treasure Island (FL): StatPearls Publishing LLC, 2024.
[14] SALLOWAY SP, SEVINGY J, BUDUR K, et al.Advancing combination therapy for Alzheimer’s disease[J]. Alzheimer’s Dement (NY), 2020, 6(1): e12073.
[15] HAMPEL H, HARDY J, BLENNOW K, et al.The amyloid-β pathway in Alzheimer’s disease[J]. Mol Psychiatry, 2021, 26(10): 5481-5503.
[16] ZHANG H, WEI W, ZHAO M, et al.Interaction between Aβ and Tau in the pathogenesis of Alzheimer’s disease[J]. Int J Biol Sci, 2021, 17(9): 2181-2192.
[17] VOYTYUK I, DE STROOPER B, CHáVEZ-GUTIéRREZ L. Modulation of γ- and β-Secretases as early prevention against Alzheimer’s disease[J]. Biol Psychiatry, 2018, 83(4): 320-327.
[18] JACOBSEN H, OZMEN L, CARUSO A, et al.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice[J]. J Neurosci, 2014, 34(35): 11621-11630.
[19] SEVIGNY J, CHIAO P, BUSSIèRE T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease[J]. Nature, 2016, 537(7618): 50-56.
[20] RAHMAN A, HOSSEN MA, CHOWDHURY MFI, et al.Aducanumab for the treatment of Alzheimer’s disease: a systematic review[J]. Psychogeriatrics, 2023, 23(3): 512-522.
[21] MINTUN MA, LO AC, DUGGAN EC, et al.Donanemab in early Alzheimer’s disease[J]. N Engl J Med, 2021, 384(18): 1691-1704.
[22] SCHIMRIGK S, MARZINIAK M, NEUBAUER C, et al.Dronabinol is a safe long-term treatment option for neuropathic pain patients[J]. Eur Neurol, 2017, 78(5-6): 320-329.
[23] MATTACE RG, RUSSO R, CALIGNANO A, et al.Palmitoylethanolamide in CNS health and disease[J]. Pharmacol Res, 2014, 86: 32-41.
[24] PETROSINO S, DI MARZO V.The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations[J]. Br J Pharmacol, 2017, 174(11): 1349-1365.
[25] BORTOLETTO R, BALESTRIERI M, BHATTACHARYYA S, et al.Is it time to test the antiseizure potential of palmitoylethanolamide in human studies? A systematic review of preclinical evidence[J]. Brain Sci, 2022, 12(1): 101.
[26] SCUTERI D, GUIDA F, BOCCELLA S, et al.Effects of palmitoylethanolamide (PEA) on nociceptive, musculoskeletal and neuropathic pain: systematic review and meta-analysis of clinical evidence[J]. Pharmaceutics, 2022, 14(8): 1672.
[27] ZHAO L, JING XJ, JIANG SJ.Treatment of Parkinson’s disease with selegiline combined with levodopa in 51 cases[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2022, 26(2): 406-409.
[28] SI HT, REN HY, WANG XB, et al.Analysis of the effect of selegiline combined with levodopa in the treatment of Parkinson’s disease patients[J]. Clinical ＆ Medical Engineering(临床医学工程), 2024, 31(1): 23-24.
[29] JENNER P.Stalevo^® : a pioneering treatment for off periods in Parkinson’s disease[J]. Eur J Neurol, 2023, 30(Suppl 2): 3-8.
[30] MA LL, ZHANG L, WU YY.Clinical study of levodopa/carbidopa combined with entacarbine in the treatment of Parkinson’s disease[J]. Journal of Medical Forum(医药论坛杂志), 2022, 43(13): 49-52.
[31] ZHANG BB, HOU Y, LOU W.The therapeutic effect of pramipexole combined with dopamine hydrazine tablets in the treatment of Parkinson’s disease and its effect on serum BDNF 5-HT NE[J]. Hebei Medicine, 2018, 24(8): 1297-1301.
[32] LIU SM, MA N, NIU ZL, et al.The efficacy of pramipexole combined with doposazid tablets in the treatment of Parkinson’s disease patients[J]. Medical Journal of Chinese People’s Health(中国民康医学), 2024, 36(2): 9-11.
[33] DONNELLY CJ, GRIMA JC, SATTLER R.Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?[J]. Neurodegener Dis Manag, 2014, 4(6): 417-437.
[34] LIU J, WANG F.Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications[J]. Front Immunol, 2017, 8: 1005.
[35] NDAYISABA A, KAINDLSTORFER C, WENNING GK.Iron in neurodegeneration-cause or consequence?[J]. Front Neurosci, 2019, 13: 180.
[36] SHAN G, LI Y, ZHANG J, et al.A small molecule enhances RNA interference and promotes microRNA processing[J]. Nat Biotechnol, 2008, 26(8): 933-940.
[37] BADAL S, HER YF, MAHER LJ.Nonantibiotic effects of fluoroquinolones in mammalian cells[J]. J Biol Chem, 2015, 290(36): 22287-22297.
[38] CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA, et al.Trial of celecoxib in amyotrophic lateral sclerosis[J]. Ann Neurol, 2006, 60(1): 22-31.
[39] GOLDSHTEIN H, MUHIRE A, PETEL LV, et al.Efficacy of ciprofloxacin/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2020, 7(10): 1883-1897.
[40] CHEN WY, BAILEY EC, MCCUNE SL, et al.Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase[J]. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(11): 5798-5803.
[41] GUIBERSON NGL, PINEDA A, ABRAMOV D, et al.Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones[J]. Nat Commun, 2018, 9(1): 3986.
[42] FELS JA, DASH J, LESLIE K, et al.Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts[J]. Ann Clin Transl Neurol, 2022, 9(10): 1551-1564.
[43] SUN Y, LI X, BEDLACK R.An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2023, 23(1): 1-7.
[44] WANG X, SUN G, FENG T, et al.Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression[J]. Cell Research, 2019, 29(10): 787-803.
[45] LIU QQ, DING SK, SHANG YZ.Research progress in the treatment of neurodegenerative diseases with traditional Chinese medicine[J]. Journal of Chengde Medical University(承德医学院学报), 2021, 38(6): 518-521.